Mabpharm Limited Share Price

2181

KYG5780F1046

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 09:08:27 30/09/2026 BST			5-day change	1st Jan Change
0.4500 ^HKD	-5.26%		+20.00%	-10.00%

08-28	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-24	Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection)	CI

Mabpharm Ltd is an investment holding company primarily engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Companyâ€™s main products include CMAB009 Enlituo (cetuximab Î² injection), CMAB007 Aomaishu (Omalizumab Î± for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Companyâ€™s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The Company is also engaged in the transfer of intellectual property. The Company mainly conducts its business in the domestic market.

Employees

394

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
30/09/26	HK$0.4500	-5.26%	56,000
29/09/26	HK$0.4750	-4.04%	0
28/09/26	HK$0.4950	-2.94%	0
25/09/26	HK$0.5100	+29.11%	16,000
24/09/26	HK$0.3950	+5.33%	46,000

Delayed Quote Hong Kong S.E.

More quotes

Market Cap	1.59B 1.86B 237M 210M 196M 179M 336M 22.81B 342M 2.37B 920M 11.62B 889M 870M 37.44B	P/E 2024	-8.48x	P/E 2025	44.9x
Enterprise Value	1.8B 2.11B 269M 239M 223M 204M 382M 25.94B 389M 2.7B 1.05B 13.21B 1.01B 989M 42.57B	EV / Sales 2024	5.06x	EV / Sales 2025	3.2x
Free-Float	22.82%	Yield 2024 *	-	Yield 2025	-

08-28	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-24	Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection)	CI
06-09	Mabpharm Limited Receives Approval For New Drug Application Of CMAB807 Denosumab Injection From National Medical Products Administration	CI
06-09	Mabpharm's Application for Osteoporosis Drug Approved in China	MT
03-26	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-26	Mabpharm FY profit and total comprehensive income attributable rmb57.1 million	RE
12-05	Mabpharm Limited Announces Change of Address of Principal Place of Business in Hong Kong	CI
31/10/25	Mabpharm Limited Announces Board and Committee Changes, Effective October 31, 2025	CI
28/08/25	Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
27/03/25	Mabpharm Shrinks Loss by 39% in 2024	MT
26/03/25	Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03/01/25	Mabpharm's Infliximab Drug Receives Approval from Pakistan's Drug Regulator	MT
02/01/25	Mabpharm Limited Announces Approval from the Drug Regulatory Authority of Pakistan on the Registration of Core Product, CMAB008 (Infliximab for Injection)	CI

13/11/23	Cryopyrin-Associated Periodic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	AQ
20/07/21	Mabpharm : Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter	AQ
30/04/21	Mabpharm : POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, APRIL 30, 2021	PU
21/04/21	Mabpharm : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 18, 2021	PU
12/04/21	Mabpharm : (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF CMAB807 (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE CLINICAL TRIALS AGREEMENT AND THE CDMO AGREEMENT AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING	PU

1 day	-5.26%
1 week	+20.00%
1 month	+1.12%
3 months	+7.14%
6 months	-10.00%
Current year	-10.00%

1 week	0.4	0.54
1 month	0.35	0.54
Current year	0.31	0.81
1 year	0.31	0.81
3 years	0.25	0.94
5 years	0.25	1.2
10 years	0.25	1.8

Mabpharm Limited Share Price

Stocks

2181

KYG5780F1046

Biotechnology & Medical Research

Valuation: Mabpharm Limited

Chart: Mabpharm Limited

Latest news: Mabpharm Limited

Press Releases: Mabpharm Limited

Quotes and Performance

Price Extremes

Managers and Directors: Mabpharm Limited

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Hao Wang CEO	Chief Executive Officer	57	27/10/2020
Sheng Hou PRN	Corporate Officer/Principal	49	30/11/2023
Jing Tao PRN	Corporate Officer/Principal	53	02/08/2018

Director	Title	Age	Since
Hao Wang BRD	Director/Board Member	57	19/07/2018
Yun Feng Li BRD	Director/Board Member	49	19/07/2018
Shu Ge Jiao CHM	Chairman	60	19/07/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MABPHARM LIMITED	-5.26%	+20.00%	-28.57%	-5.26%	237M
WUXI APPTEC CO., LTD.	+4.16%	-0.36%	+49.37%	+94.17%	74.46B
ARGENX SE	-0.61%	+0.69%	+36.36%	+82.72%	60.14B
LONZA GROUP AG	-2.54%	-0.21%	+6.34%	+31.72%	48.15B
IQVIA HOLDINGS INC.	-3.02%	-2.67%	+37.26%	+32.51%	44.25B
REVOLUTION MEDICINES, INC.	+0.31%	+7.94%	+340.88%	+643.82%	43.99B
BEONE MEDICINES AG	-1.96%	-1.71%	+5.30%	+99.46%	41.61B
CELLTRION, INC.	+3.32%	+3.49%	+11.18%	+51.23%	29.97B
WUXI BIOLOGICS (CAYMAN) INC.	+4.77%	+6.16%	+36.77%	+22.78%	29.31B
INSMED INCORPORATED	-4.86%	-8.24%	-24.60%	+330.06%	24.93B
Average	-0.57%	+3.77%	+47.03%	+138.32%	39.7B
Weighted average by Cap.	+0.17%	+1.84%	+60.01%	+145.69%

	2024	2025
Net sales	258M 302M 38.55M 34.23M 31.97M 29.16M 54.71M 3.71B 55.63M 387M 150M 1.89B 145M 142M 6.09B	646M 757M 96.45M 85.64M 79.99M 72.95M 137M 9.29B 139M 967M 375M 4.73B 362M 354M 15.25B
Net income	-128M -150M -19.1M -16.96M -15.84M -14.45M -27.11M -1.84B -27.56M -192M -74.19M -937M -71.71M -70.15M -3.02B	57.13M 66.92M 8.53M 7.57M 7.07M 6.45M 12.1M 821M 12.31M 85.53M 33.13M 418M 32.02M 31.32M 1.35B
Net Debt	222M 260M 33.18M 29.46M 27.51M 25.09M 47.09M 3.2B 47.88M 333M 129M 1.63B 125M 122M 5.24B	217M 255M 32.47M 28.83M 26.92M 24.56M 46.08M 3.13B 46.85M 326M 126M 1.59B 122M 119M 5.13B